investing

The Best Stock in New York: Intercept Pharmaceuticals

We analyzed publicly traded companies based in the Empire State to identify the best stock in New York to buy now.

We scoured the nation to identify the best stock in every state. Intercept Pharmaceuticals (symbol ICPT) is the publicly traded company we picked in New York. The company headquarters is located in New York City.

A word of caution: Since we selected a single stock from each state (plus one from D.C), and choices in some states are sparse, a few of our picks are best suited to investors comfortable with a higher degree of risk. This is not necessarily one of our 51 favorite stocks in the entire U.S., in other words.

Intercept Pharmaceuticals by the Numbers

  • Headquarters: New York City
  • Share price: $130.57
  • Market value: $3.3 billion
  • Price-earnings ratio: NA

(Prices and data are as of June 22, 2017)

Intercept is a biotech company focused on treatments for liver diseases. The company celebrated its first major victory last year when its key drug, Ocaliva, received FDA approval to treat primary biliary cholangitis, a rare liver disease that affects a person’s bile ducts. The drug is the first commercially successful treatment for the disease in 20 years, and it should drive sales growth henceforth, says Value Line analyst Nira Maharaj. But the biggest opportunity (and risk) for the drug is its potential approval to treat nonalcoholic steatohepatitis (NASH), a common but serious liver condition with limited treatments. NASH represents a potential $30 billion market in annual sales globally, says Morningstar analyst Kelsey Tsai. And though many firms are vying to be the first to address the disease, Intercept’s drug is the leader in the race. There is serious concern that Intercept may lose that race, but Wedbush analyst Liana Moussatos is encouraged by Ocaliva’s success in treating NASH in recent clinical trials, one of which was stopped a year early because of better-than-expected efficacy. Moussatos’s $231 12-month price target is nearly double the current share price.

Most Popular

Senate Passes $3,000 Child Tax Credit for 2021
Coronavirus and Your Money

Senate Passes $3,000 Child Tax Credit for 2021

The provision would temporarily increase the child tax credit to $3,000 or $3,600 per child for most families and have 50% of it paid in advance by th…
March 6, 2021
Senate Passes Bill with More "Targeted" Stimulus Payments
Coronavirus and Your Money

Senate Passes Bill with More "Targeted" Stimulus Payments

The Senate finally passes the $1.9 trillion COVID-relief bill. But fewer people will get a third stimulus check under the Senate version than under th…
March 6, 2021
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021

Recommended

Bonds: 10 Things You Need to Know
Investing for Income

Bonds: 10 Things You Need to Know

Bonds can be more complex than stocks, but it's not hard to become a knowledgeable fixed-income investor.
July 22, 2020
Why I Like Ginnie Mae Funds Now
Investing for Income

Why I Like Ginnie Mae Funds Now

A portfolio of mortgages should retain their value better than ordinary bonds if interest rates rise.
February 28, 2021
2 Top-Tier T. Rowe Price Mutual Funds
mutual funds

2 Top-Tier T. Rowe Price Mutual Funds

T. Rowe Price's mutual funds typically stand out among their peers, but these two selections provide elite equity and bond exposure for this point in …
February 24, 2021
How Green Are Your Bonds?
Becoming an Investor

How Green Are Your Bonds?

Fixed-income investors can make an environmental impact, too.
February 23, 2021